Literature DB >> 11187914

Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92.

D O Harms1, G E Janka-Schaub.   

Abstract

The German Co-operative Study Group COALL for treatment of acute lymphoblastic leukemia (ALL) in childhood started the first trial in 1980. This report gives an overview of the long-term results of the four consecutive studies COALL-82, COALL-85, COALL-89 and COALL-92. Besides improvement in long-term survival major objectives were reduction of treatment-related toxicity by transferring asparaginase (ASP) from induction therapy to intensive phase and omitting CNS irradiation by stepwise increase of the initial white blood count (WBC) up to 50 x 10(9)/l (exception T-ALL) as criterion for irradiation. In study COALL-85 in high risk patients slow vs rapid rotational treatment was randomized. In study COALL-92 initial response to daunorubicin (DNR) as a 1-h vs 24-h infusion and its prognostic value was investigated. Furthermore, 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) were randomized in maintenance treatment. In total, 1191 eligible patients were enrolled. Induction treatment without ASP has been shown to be as effective and less hazardous than the former four-drug induction. CNS control could be obtained in most without cranial irradiation (CNS relapse-free survival >95%). The leukemic cell kill with a 24-h DNR infusion was equivalent to that of a 1-h infusion. DNR response was of less prognostic significance than prednisone response. The rapid rotation regimen failed to improve outcome as well as 6-TG in maintenance treatment. However, intensification of systemic treatment resulted in an increase in overall event-free survival (EFS) to approximately 80% which is comparable to other groups.

Entities:  

Mesh:

Year:  2000        PMID: 11187914     DOI: 10.1038/sj.leu.2401974

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

Review 1.  International collaboration on childhood leukemia.

Authors:  Ching-Hon Pui; Raul C Ribeiro
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.

Authors:  Franziska Schramm; Udo Zur Stadt; Martin Zimmermann; Norbert Jorch; Arnulf Pekrun; Arndt Borkhardt; Thomas Imschweiler; Holger Christiansen; Jörg Faber; Irene Schmid; Tobias Feuchtinger; Gerhard Beron; Monique L den Boer; Rob Pieters; Martin A Horstmann; Gritta E Janka-Schaub; Gabriele Escherich
Journal:  Blood Adv       Date:  2019-11-26

Review 3.  Optimizing treatment in paediatric rheumatology--lessons from oncology.

Authors:  Tim Niehues
Journal:  Nat Rev Rheumatol       Date:  2015-04-21       Impact factor: 20.543

4.  Prognostic significance of survivin in pediatric acute lymphoblastic leukemia.

Authors:  Asmaa M Esh; Maha Atfy; Nashwa A Azizi; Mohamed M El Naggar; Ebtesam E Khalil; Layla Sherief
Journal:  Indian J Hematol Blood Transfus       Date:  2011-02-12       Impact factor: 0.900

Review 5.  Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

Authors:  Ching-Hon Pui; Charles G Mullighan; William E Evans; Mary V Relling
Journal:  Blood       Date:  2012-06-22       Impact factor: 22.113

6.  Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma.

Authors:  Hideaki Nitta; Yasuhito Terui; Masahiro Yokoyama; Yuko Mishima; Noriko Nishimura; Kyoko Ueda; Yoshiharu Kusano; Naoko Tsuyama; Kengo Takeuchi; Yoshinobu Kanda; Kiyohiko Hatake
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

7.  Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.

Authors:  Hiroki Hori; Tooru Kudoh; Shinichiro Nishimura; Megumi Oda; Makoto Yoshida; Junichi Hara; Akio Tawa; Ikuya Usami; Akihiko Tanizawa; Keiko Yumura-Yagi; Koji Kato; Ryoji Kobayashi; Yoshihiro Komada; Keitaro Matsuo; Keizo Horibe
Journal:  Int J Clin Oncol       Date:  2016-11-17       Impact factor: 3.402

8.  Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols.

Authors:  Amy Holleman; Monique L den Boer; Meyling H Cheok; Karin M Kazemier; Deqing Pei; James R Downing; Gritta E Janka-Schaub; Ulrich Göbel; Ulrike B Graubner; Ching-Hon Pui; William E Evans; Rob Pieters
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

Review 9.  Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues.

Authors:  Nobuko Hijiya; Kirsten K Ness; Raul C Ribeiro; Melissa M Hudson
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

10.  A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.

Authors:  Alexander Teml; Matthias Schwab; Daan W Hommes; Sven Almer; Milan Lukas; Thomas Feichtenschlager; Timothy Florin; Julia Seiderer; Wolfgang Petritsch; Bernd Bokemeyer; Wolfgang Kreisel; Klaus R Herrlinger; Peter Knoflach; Bruno Bonaz; Thomas Klugmann; Hans Herfarth; Nikolaus Pedarnig; Walter Reinisch
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.